Indian biologics market is estimated to grow at a CAGR of 10.2% during the forecast period. A significant rise in the launches of biologics is supporting to drive market growth. For instance, in October 2020, Cadila Pharmaceuticals revealed two similar biologics in India, which include Cadalimab and NuPTH. Cadalimab is a similar biologic of the auto-immune treatment and NuPTH is a teriparatide similar biologic. Since July 2020, the company has introduced four new products in India. As a similar biologic of teriparatide, NuPTH is a kind of parathyroid hormone utilized for osteoporosis treatment by stimulating bone formation.
Browse the full report description of "Indian Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/indian-biologics-market
This drug can also be utilized in other patient groups at augmented risk of fracture. Additionally, Adalimumab is an antibody therapy for inflammatory conditions. These conditions include several kinds of inflammatory bowel disease (IBD), arthritis, and psoriasis. As the US FDA approved first human monoclonal antibody treatment, Adalimumab is marketed with the brand name Humira since 2003. In January 2018, Glenmark Pharmaceuticals Ltd. declared the introduction of Adalimumab biosimilar to treat rheumatoid arthritis and plaque psoriasis. It is marketed by the company with the brand name ADALY.
ADALY (Adalimumab) is a tumor necrosis factor (TNF) inhibiting, anti-inflammatory biologic that decreases inflammatory response. Further, in April 2019, Intas Pharmaceuticals declared the introduction of a ‘similar biologic’ of trastuzumab named Eleftha in India. This new drug claims that it will reduce the cost of breast cancer therapy by approximately 65%. It is a similar biologic of Herceptin (trastuzumab), which is a blockbuster breast cancer drug by Roche approved by the European Medicines Agency (EMA) in August 2000 and by the US FDA in September 1998. Herceptin is aimed to treat gastric and breast cancers.
Scope of the Indian Biologics Market
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
Indian Biologics Market-Segmentation
By Product
By Application